Ortiz IFJ, Morales MI, Gil AA, Reyna FJ, Benitez A, Aldrete VJ, Luna LD

Language: Spanish
References: 33
Page: 361-371
PDF size: 329.73 Kb.

ABSTRACT

Background: Bacterial resistance is one of the greatest clinical challenges prevalence now is limiting because the prescription of antibiotics that were effective until recently.
Objetive: To present an analysis of the epidemiological behavior and susceptibility of diverse pathogenic microorganisms isolated between 2004 and 2008 in various hospitals worldwide before the principal known antimicrobials.
Materials and methods: Review and clinical analysis of the results obtained in the worldwide tigecycline evaluation and epidemiological surveillance trial (TEST) carried out from 2004 to 2008 to evaluate the bacterial sensitivity of strains obtained from patients with different infectious processes, both nosocomial as well as communitarian, to multiple antibiotics compared to tigecycline, in addition to an analysis of its potential use in other infectious pathologies.
Results: The study included the participation of 130 hospitals with a total of 102, 829 cultures positive for the pathogenic microorganisms responsible for intra-abdominal infections, skin infections and soft tissue infections, among others. The results of this trial are presented in tables regionalized for each of the participating continents and regions. An analysis using the results obtained in the worldwide resistance tables was carried out to establish a globalized and regionalized panorama for Latin America, specifically Mexico, as well as a clinical correlation of the potential benefits and risks of the clinical use of tigecycline.
Conclusions: The results observed in TEST show us that in Latin America, and specifically in Mexico, the observed percentages of susceptibility for the principal Gram positive and Gram negative microorganisms challenged exhibit a high susceptibility to tigecycline (98.74 and 99.63%, respectively) indicating this innovative agent is an excellent alternative for the monotherapeutic management of serious infections.

REFERENCES

1. Lipschit M. Fears growing over bacteria resistant to antibiotics. New York Times 1995 12 Sep. C1.

2. Wenzel RP. The antibiotic pipeline-challenges, cost and values. N Eng J Med 2004;351:523-26.

3. Weber JT. Community associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2005;41:S269-S72.

4. Tenover FC. Vancomycin-resistent Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004;48:275-80.

5. Reyna FJ, Ramírez LA, Villeda GG, et al. Primer informe de Staphylococcus haemolyticus con susceptibilidad reducida a vancomicina aislado de un paciente con neuroinfección neonatal en una institución mexicana. Gac Med Mex 2007;143:165- 67.

6. Cornejo P, Velázquez A. Tendencia del perfil de sensibilidad antimicrobiana de los aislamientos de sangre en un hospital oncológico (1998-2003). Salud Pública de México 2005;47(4):288-93.

7. Paredes P, Rivera MC, Duran PE, et al. Estudio bacteriológico del paciente con peritonitis debida a diálisis peritoneal continua ambulatoria en el Hospital General de México. Med Int Mex 2006;22:172-82.

8. Tinoco JC, Sifuentes O, Donis H y col. Tasas de resistencia en Pseudomonas aeruginosa y Acinetobacter spp, aisladas de hemocultivos. Programa de Resistencia bacteriana en México. Enf Infecc Microbiol 2002;22:81.

9. http://www.testsurveillance.com/index.php?key=097b78da12 a02f6a2c80e7c65e60e768.

10. Bouchillon SK, Hoban DJ, Johnson BM, Stevens TM, y col. Evaluación in vitro de tigeciclina y compuestos comparativos en 3,049 aislados clínicos: 2001 a 2002. Diagnostic Microbiology and Infectious Diseases 2005;51:291-95.

11. Bouchillon SK, Hoban DJ, Johnson BM, y col. Actividad in vitro de tigeciclina contra 3,989 aislados clínicos gramnegativos y grampositivos del Estudio de Evaluación y Vigilancia de Tigeciclina en EU. (Programa TEST; 2004). Diagnostic Microbiology and Infectious Disease 2005;52:172-79.

12. Hoban DJ, Bouchillon SK, Johnson BM, et al. Actividad in vitro de tigeciclina contra 6,792 aislados clínicos gramnegativos y grampositivos del Estudio de Evaluación y Vigilancia de Tigeciclina Mundial (Programa TEST; 2004). Diagnostic Microbiology and Infectious Disease 2005;52:215-27.

13. Rossi F, García P, Ronzon B, et al. Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the Glycylcycline Tigecycline and others antibiotics. BJID 2008;12:405-15.

14. National Committee for clinical Laboratory standards, 2003. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M7-A5, vol 20. National Committee for clinical Laboratory standards. Wayne. Pa.

15. Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem-cilastatin in patient with complicated intrabdominal infections. BMC Infectious Diseases 2005;5:88-93.

16. Babinchack T, Grosse EE, Dartois N, et al. The efficacy and safety of Tigecycline for the treatment of complicated intraabdominal infections: Analysis of pooled clinical trials data. CID 2005;41:S354-67.

17. Mallick R, Sun S, Schell S. Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections. Evidence for pooled clinical studies comparing Tigecycline with Imipenem-cilastatin. Surg Infect (Larchmt) 2007;8(2):159-72.

18. Betriu C, Culebras E, Gómez M, et al. Activity in vitro of Tigecycline versus Bacteroides species. Journal of Antimicrob Chemother 2005;56:349-52.

19. Cortez UM, Herrera CG. Complicaciones de la apendicectomía laparoscópica. En: Complicaciones en cirugía laparoscópica y toracoscópica. México: Alfil, 2007;p:138.

20. Mathur P. Infections in traumatized patients: a growing medico- surgical concern. Indian J Med Microbiol 2008;26(3):212- 16.

21. Granchi TS, Abikhaled JA, Hirshberg A, et al. Patterns of microbiology in intra-abdominal packing for trauma. J Trauma 2004;56:45-51.

22. Russell GP, Green SL, Klin SR, et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tygecycline for the complicated skin and skin structure infections in hospitalized patient. Clin Therapeutics 2004;26:704-14.

23. Sacchidanand S, Penn R, Embil J, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized double blind trial. Inter J Infect Dis 2005;9:251-61.

24. Breedt J, Teras J, Gardovskis J. Safety and efficacy of tigecycline in the treatment of skin and skin structure infections. Results of a double-blind phase 3 comparison study with vancomycin- aztreonam. Antimicrob agents Chemother 2005;49:4658-66.

25. Mäkinen J, Johansson J, Tomas C, et al. Morbidity of 10,110 hysterectomies by type of approach. Human Rep 2001;16(7):1473-78.

26. Culligan P, Heit M, Blackwell L. Bacterial colony counts during vaginal surgery. Infect Dis Obstet Gynecol 2003;11:161-65.

27. Sader HS, Jones RN, Stilwell MG, et al. Actividad de tigecilina examinada contra 26,474 aislados de infecciones del torrente sanguíneo: una recolección de seis continentes. Diagnostic Microbiology and Infectious Disease 2005;52:181-86.

28. Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in the community-acquired pneumonia. Diag Microbiol Infect Dis 2008;61(3):329-38.

29. Timurkaynak FA, Arslan HA, Kurt AO, et al. In vitro activity of tigecycline against resistant microorganisms isolated from burn patients. Burns 2008;34:1033-36.

30. Frampton JE, Curran MP. Tigeciclina. Drugs 2005;65:2623-35.

31. Muralidharan G, Fruncillo RJ, Micallizi M, et al. Effects of age and gender of the pharmacokinetics of single dose tigecycline in healthy subjects. Antimicrob Agents Chemother 2005;49:1656-59.

32. Muralidharan G, Micallizi M, Speth J, et al. Pharmacokinetics of tigecycline Alters single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220-29

33. Dilip N. Tigeciclina: evidencia clínica y posicionamiento en el formulario. International Journals of Antimicrobial Agents 2005;25:185-92.